A208340 Stock Overview
PharmAbcine Inc., a clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PharmAbcine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,915.00 |
| 52 Week High | ₩4,630.00 |
| 52 Week Low | ₩900.00 |
| Beta | 0.91 |
| 11 Month Change | 0% |
| 3 Month Change | -8.91% |
| 1 Year Change | 2.64% |
| 33 Year Change | -80.09% |
| 5 Year Change | -89.81% |
| Change since IPO | -88.54% |
Recent News & Updates
Shareholder Returns
| A208340 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | 0.9% |
| 1Y | 2.6% | 23.1% | -3.4% |
Return vs Industry: A208340 exceeded the KR Biotechs industry which returned -2.7% over the past year.
Return vs Market: A208340 matched the KR Market which returned 2.1% over the past year.
Price Volatility
| A208340 volatility | |
|---|---|
| A208340 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A208340 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A208340's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 44 | Jin-San Yoo | www.pharmabcine.com |
PharmAbcine Inc., a clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for various spectrum of indications from oncology, immuno-oncology, ophthalmology, and pulmonology. The company also develops TTAC0001, an anti-angiogenic that neutralizes the VEGF/VEGFR2 pathway; PMC-309, a monoclonal antibody that targets the negative immune checkpoint human VISTA; PMC-402, a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization for solid tumors; and PMC-403, a monoclonal antibody that targets the human TIE2, which regulate the angiogenesis and vessel maturation in endothelial cells.
PharmAbcine Inc. Fundamentals Summary
| A208340 fundamental statistics | |
|---|---|
| Market cap | ₩88.01b |
| Earnings (TTM) | -₩14.25b |
| Revenue (TTM) | ₩74.96m |
1,174x
P/S Ratio-6.2x
P/E RatioIs A208340 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A208340 income statement (TTM) | |
|---|---|
| Revenue | ₩74.96m |
| Cost of Revenue | ₩128.52m |
| Gross Profit | -₩53.55m |
| Other Expenses | ₩14.19b |
| Earnings | -₩14.25b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -471.86 |
| Gross Margin | -71.44% |
| Net Profit Margin | -19,004.64% |
| Debt/Equity Ratio | 29.0% |
How did A208340 perform over the long term?
See historical performance and comparison